Keros Therapeutics (NASDAQ:KROS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Keros Therapeutics (NASDAQ:KROS) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other equities analysts have also recently issued reports on KROS. Zacks Research cut Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Oppenheimer reiterated an “outperform” rating and issued a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Finally, Bank of America boosted their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and an average price target of $21.86.

Keros Therapeutics Trading Up 0.4%

Shares of NASDAQ KROS opened at $11.35 on Friday. The stock has a market cap of $345.83 million, a P/E ratio of 6.24 and a beta of 0.87. The business’s fifty day simple moving average is $17.22 and its 200-day simple moving average is $17.05. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The company had revenue of $0.39 million for the quarter, compared to analyst estimates of $3.66 million. During the same period in the previous year, the firm earned ($1.14) earnings per share. The company’s revenue for the quarter was down 87.2% compared to the same quarter last year. On average, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KROS. Franklin Resources Inc. boosted its holdings in Keros Therapeutics by 245.5% in the second quarter. Franklin Resources Inc. now owns 132,301 shares of the company’s stock valued at $1,766,000 after purchasing an additional 94,006 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Keros Therapeutics by 154.2% in the third quarter. Assenagon Asset Management S.A. now owns 257,518 shares of the company’s stock valued at $4,074,000 after purchasing an additional 156,221 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Keros Therapeutics by 107.4% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 265,707 shares of the company’s stock worth $3,547,000 after purchasing an additional 137,604 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $557,000. Finally, Western Standard LLC lifted its position in shares of Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after buying an additional 654,989 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.